Phase 3 Clinical Trials With Primary Completion Dates in February 2022

This is a list of Phase 3 trials with primary completion dates in February 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ASND Ascendis Pharma A/S 2022-02-01 Phase 3 NCT04701203 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
BLUE bluebird bio, Inc. 2022-02-01 Phase 3 NCT02906202 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
CLVS Clovis Oncology, Inc. 2022-02-01 Phase 3 NCT02975934 A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
CYDY CytoDyn Inc. 2022-02-01 Phase 3 NCT04901689 Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
EIGR Eiger BioPharmaceuticals, Inc. 2022-02-01 Phase 3 NCT04727424 Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
NEPH Nephros, Inc. 2022-02-01 Phase 3 NCT02757872 Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
SAGE Sage Therapeutics, Inc. 2022-02-01 Phase 3 NCT03864614 A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)